DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m Daiichi Sankyo has finalised the acquisition of intellectual ...

Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...

The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...

Under that agreement, Daiichi Sankyo gained exclusive global rights to develop and commercialise gatipotuzumab as an antibody-drug conjugate (ADC). Gatipotuzumab serves as the antibody component ...

Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...

Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...

British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...

Tokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) has been approved by the US Food and Drug ...

DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer ...